Brinjikji Waleed, Lehman Vance T, Kallmes David F, Rabinstein Alejandro A, Lanzino Giuseppe, Murad Mohammad H, Mulvagh Sharon, Klaas James, Graff-Radford Jonathan, DeMarco Kevin J, Huston Iii John
Department of radiology, Mayo Clinic, 200, 1st Street SW, 55905 Rochester, MN, United States.
Department of radiology, Mayo Clinic, 200, 1st Street SW, 55905 Rochester, MN, United States.
J Neuroradiol. 2017 Jul;44(4):234-240. doi: 10.1016/j.neurad.2016.12.004. Epub 2017 Feb 7.
Prior studies have demonstrated that statin use stabilizes and diminishes atherosclerotic lesions. The main objective of this systematic review and meta-analysis was to study the effects of statin therapy on carotid plaque composition as seen on serial high-resolution carotid plaque MRI. We hypothesized that statin therapy would result in significant improvements in lipid-rich-necrotic-core (LRNC) volumes, wall volumes and lumen volumes.
Prospective studies using serial high-resolution carotid plaque MRI (1.5 or 3T only) in patients on statin therapy to document changes in carotid plaque composition were included. All studies had a minimum of 10 patients and minimum follow-up duration of 3 months. Outcomes included change in LRNC volume, wall volume, and lumen volume at: (1) 1-6 months; (2) 7-12 months; (3) >12 months following initiation of statin therapy; and (4) at last follow-up. Meta-analysis was performed using the random effects model. Results were reported as weighted mean differences (WMD) and 95% confidence interval (CI).
Seven studies including 361 patients were included. There was no significant change in carotid wall volume or lumen volume at any time points. While there was no significant difference in LRNC at 1-6 months and at 7-12 months following initiation of statin therapy; at >12 months, there was significant decrease in LRNC volume (WMD=-9.9mm, 95% CI=-8.9, -2.3).
Our study suggests statin therapy is associated with significant reductions in LRNC at 1-year of statin therapy on serial carotid MRI. However, no significant reduction in carotid wall volume was seen.
既往研究表明,使用他汀类药物可使动脉粥样硬化病变稳定并缩小。本系统评价和荟萃分析的主要目的是研究他汀类药物治疗对连续高分辨率颈动脉斑块MRI所见颈动脉斑块成分的影响。我们假设他汀类药物治疗将使富含脂质的坏死核心(LRNC)体积、管壁体积和管腔体积得到显著改善。
纳入前瞻性研究,这些研究对接受他汀类药物治疗的患者使用连续高分辨率颈动脉斑块MRI(仅1.5或3T)记录颈动脉斑块成分的变化。所有研究至少有10名患者,最短随访时间为3个月。结局包括在以下时间点LRNC体积、管壁体积和管腔体积的变化:(1)1 - 6个月;(2)7 - 12个月;(3)他汀类药物治疗开始后>12个月;(4)最后一次随访时。采用随机效应模型进行荟萃分析。结果以加权平均差(WMD)和95%置信区间(CI)报告。
纳入7项研究,共361例患者。在任何时间点,颈动脉管壁体积或管腔体积均无显著变化。虽然在他汀类药物治疗开始后的1 - 6个月和7 - 12个月,LRNC无显著差异;但在>12个月时,LRNC体积显著减小(WMD = -9.9mm,95%CI = -8.9,-2.3)。
我们的研究表明,在连续颈动脉MRI上,他汀类药物治疗1年后,LRNC显著减少。然而,未观察到颈动脉管壁体积有显著减小。